G. Bianchini

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.

P. Valagussa, S. Russo, R. Greil, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

292P Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial

F. Puglisi, M. Benelli, G. Arpino, 2021, Annals of Oncology.

A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes

Y. Qi, G. Hortobagyi, L. Pusztai, 2012, British Journal of Cancer.

Alternative methods to determine the δ2H-δ18O relationship: An application to different water types

F. Comiti, G. Chiogna, L. Carturan, 2020 .

LBA12 Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial

B. Győrffy, M. Dugo, M. Callari, 2021, Annals of Oncology.

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.

A. Swat, R. Deurloo, G. Bianchini, 2024, Annals of oncology : official journal of the European Society for Medical Oncology.